The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma

Cell Death and Differentiation

Volumn 21, Issue 2, 2014, Pages 247-257

  Sanchez Tillo E ^a   Fanlo, L ^a,b   Siles, L ^a   Montes Moreno, S ^c   Moros, A ^a   Chiva Blanch, G ^d,e   Estruch, R ^d,e   Martinez, A ^d   Colomer, D ^a   Gyrffy, B ^f   Roue G ^a   Postigo, A ^a,g,h  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f SEMMELWEIS UNIVERSITY   (Hungary)

^g UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^h INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

mantle cell lymphoma; transcription; Wnt signaling; ZEB1

Indexed keywords

BETA CATENIN; CYTARABINE; DOXORUBICIN; GEMCITABINE; SALINOMYCIN; TRANSCRIPTION FACTOR ZEB1; WNT PROTEIN; ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; PYRAN DERIVATIVE; TRANSCRIPTION FACTOR; TUMOR MARKER; ZEB1 PROTEIN, HUMAN;

ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR GROWTH; WNT SIGNALING PATHWAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; GENETICS; HEK293 CELL LINE; LYMPHOMA, MANTLE-CELL; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; EPITHELIAL-MESENCHYMAL TRANSITION; HEK293 CELLS; HOMEODOMAIN PROTEINS; HUMANS; LYMPHOMA, MANTLE-CELL; MICE; PYRANS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84892385077     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.123     Document Type: Article

References (60)

1. Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416-3423.
2. Gesk S, Klapper W, Martín-Subero JI, Nagel I, Harder L, Fu K et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 2006; 108: 1109-1110. (Pubitemid 44154656)
3. Rizzatti EG, Falcão RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFb signalling pathways. Br J Haematol 2005; 130: 516-526. (Pubitemid 43899754)
4. Roué G, Pérez-Galán P, López-Guerra M, Villamor N, Campo E, Colomer D. Selective inhibition of IkappaB kinase sensitizes mantle cell lymphoma B cells to TRAIL by decreasing cellular FLIP level. J Immunol 2007; 178: 1923-1930. (Pubitemid 46154665)
5. Gelebart P, Anand M, Armanious H, Peters AC, Dien Bard J, Amin HM et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 2008; 112: 5171-5179.
6. Ortega-Paino E, Fransson J, Ek S, Borrebaeck CA. Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood 2008; 111: 1617-1624. (Pubitemid 351213453)
7. Leshchenko VV, Kuo PY, Shaknovich R, Yang DT, Gellen T, Petrich A et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010; 116: 1025-1034.
8. Kimura Y, Arakawa F, Kiyasu J, Miyoshi H, Yoshida M, Ichikawa A et al. The Wnt signaling pathway and mitotic regulators in the initiation and evolution of mantle cell lymphoma: gene expression analysis. Int J Oncol 2013; 43: 457-468.
9. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008; 111: 5142-5151.
10. Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus GS, Said JW et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001; 98: 787-794.
11. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226-8232. (Pubitemid 37549472)
12. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003; 423: 409-414. (Pubitemid 36626987)
13. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocytemacrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667. (Pubitemid 39063268)
14. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z et al. The Wnt/b-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010; 327: 1650-1653.
15. Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M, Leoni LM et al. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 3118-3123. (Pubitemid 38327744)
16. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA 2011; 108: 13253-13257.
17. Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S et al. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of b-catenin/TCF pathway. Leukemia 2007; 21: 535-540.
18. Khan NI, Bradstock KF, Bendall LJ. Activation of Wnt/b-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 2007; 138: 338-348. (Pubitemid 47035396)
19. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004; 101: 6122-6127. (Pubitemid 38520538)
20. Lento W, Congdon K, Voermans C, Kritzik M, Reya T. Wnt signaling in normal and malignant hematopoiesis. Cold Spring Harb Perspect Biol 2013; 5: a008011.
21. Valencia A, Román-Gómez J, Cervera J, Such E, Barragán E, Bolufer P et al. Wnt signaling pathway is epigenetically regulated by methylation of Wnt antagonists in acute myeloid leukemia. Leukemia 2009; 23: 1658-1666.
22. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009; 114: 1469-1476.
23. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O et al. ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857-877.
24. Jung HJ, Chen Z, McCarty N. Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. Leuk Lymphoma 2011; 52: 1066-1079.
25. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138: 645-659.
26. Clevers H, Nusse R. Wnt/b-Catenin Signaling and Disease. Cell 2012; 149: 1192-1205.
27. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006; 131: 830-840. (Pubitemid 44307069)
28. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting micro-RNAs. Nat Cell Biol 2009; 11: 1487-1495.
29. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatinremodeling protein BRG1. Oncogene 2010; 29: 3490-3500.
30. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. b-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA 2011; 108: 19204-19209.
31. Sanchez-Tillo E, de Barrios O, Siles L, Amendola PG, Darling DS, Cuatrecasas M et al. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1. Clin Cancer Res 2013; 19: 1071-1082.
32. Postigo A, Dean DC. ZEB represses transcription through interaction with the corepressor CtBP. Proc Natl Acad Sci USA 1999; 96: 6683-6688. (Pubitemid 29274943)
33. Postigo A, Dean DC. Differential expression and function of members of the zfh-1 family of zinc finger/homeodomain repressors. Proc Natl Acad Sci USA 2000; 97: 6391-6396. (Pubitemid 30412724)
34. Postigo A, Depp JL, Taylor JJ, Kroll KL.Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J 2003; 22: 2453-2462. (Pubitemid 36604984)
35. Sanchez-Tillo E, Siles L, de Barrios O, Cuatrecasas M, Vaquero EC et al. Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res 2011; 1: 897-912.
36. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13: 97-110.
37. Hill L, Browne G, Tulchinsky E. ZEB/miR-200 feedback loop: at the crossroads of signal transduction in cancer. Int J Cancer 2013; 132: 745-754.
38. Spaderna S, Schmalhofer O, Wahlbuhl M, Dimmler A, Bauer K, Sultan A et al. The transcriptional repressor ZEB1 promotes metastasis and loss of cell polarity in cancer. Cancer Res 2008; 68: 537-544. (Pubitemid 351380082)
39. Sanchez-Tillo E, Liu Y, de Barrios O, Siles L, Fanlo L, Cuatrecasas M et al. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci 2012; 69: 3429-3456.
40. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3: 185-197. (Pubitemid 37443390)
41. Blenk S, Engelmann JC, Pinkert S, Weniger M, Schultz J, Rosenwald A et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis. BMC Cancer 2008; 8: 106.
42. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates b-catenin subcellular localization and turnover. Nat Cell Biol 2000; 2: 653-660.
43. Hernandez L, Bea S, Pinyol M, Ott G, Katzenberger T, Rosenwald A et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 2005; 65: 2199-2206. (Pubitemid 40490128)
44. Pinyol M, Bea S, Pla L, Ribrag V, Bosq J, Rosenwald A et al. Inactivation of Rb1 in mantlecell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 2007; 109: 5422-5429. (Pubitemid 46890565)
45. Postigo A. Opposing functions of ZEB proteins in the regulation of the TGFb/BMP signaling pathway. EMBO J 2003; 22: 2443-2452. (Pubitemid 36604983)
46. Liu Y, Costantino ME, Montoya-Durango D, Higashi Y, Darling DS. Dean DC.The zinc finger transcription factor ZFHX1A is linked to cell proliferation by Rb-E2F1. Biochem J 2007; 408: 79-85. (Pubitemid 350158405)
47. Liu Y, El-Naggar S, Darling DS, Higashi Y, Dean DC. Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development 2008; 135: 579-588.
48. Rä ty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002; 69: 11-20. (Pubitemid 35155435)
49. Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez L, Bosch F et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffinembedded tissue. J Clin Oncol 2008; 26: 4966-4972.
50. Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004; 164: 501-510. (Pubitemid 38364666)
51. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev 2007; 26: 183-201. (Pubitemid 46452190)
52. Galimberti S, Nagy B, Benedetti E, Pacini S, Brizzi S, Caracciolo F et al. Evaluation of the MDR1, ABCG2, topoisomerases IIa and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-hyper-CVAD regimen. Leuk Lymphoma 2007; 48: 1502-1509. (Pubitemid 47272799)
53. Marce S, Molina-Arcas M, Villamor N, Casado FJ, Campo E, Pastor-Anglada M et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 2006; 91: 895-902. (Pubitemid 44023142)
54. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446.
55. Rosich L, Xargay-Torrent S, Lopez-Guerra M, Campo E, Colomer D, Roue G. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Clin Cancer Res 2012; 18: 5278-5289.
56. Bea S, Salaverria I, Armengol L, Pinyol M, Fernández V, Hartmann EM et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood 2009; 113: 3059-3069.
57. Riccioni R, Dupuis ML, Bernabei M, Petrucci E, Pasquini L, Mariani G et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor. Blood Cells Mol Dis 2010; 45: 86-92.
58. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci USA 2012; 109: 11717-11722.
59. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013; 13: 11-26.
60. Alizadeh A, Eisen M, Davis RE, Ma C, Sabet H, Tran T et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 1999; 64: 71-78. (Pubitemid 30329266)